WASHINGTON (Reuters) -Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending...
By Deena Beasley San Francisco (Reuters) - Drugmakers are prioritizing complex biotech medicines over treatments that can be given as pills because recent U.S. legislation gives...
The US economy should witness a further slowdown in 2023 With inflation still running hot and the Fed raising rates to battle it, investors need to be prudent with their investment...
Looking for the Dogs of the Dow, 2023 edition? You came to the right place. We’ll explore these 10 blue-chip dividend bargains in a moment. Collectively, they are yielding...
The market jumped on Powell's dovish comments and soft CPI reading in November However, there's been little follow-through on that rally as investors await further clues from the...
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Neutral | Strong Sell | Buy |
| Technical Indicators | Strong Buy | Strong Buy | Buy | Strong Sell | Buy |
| Summary | Strong Buy | Strong Buy | Neutral | Strong Sell | Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 248.15 | 249.83 | 246.83 | +0.15 | +0.06% | 25.98M | NASDAQ | |||
| 28.16 | 28.24 | 26.78 | -1.93 | -6.41% | 147.99M | NASDAQ | |||
| 177.88 | 180.68 | 161.17 | +17.61 | +10.99% | 304.01M | NASDAQ | |||
| 83.83 | 85.50 | 80.67 | +2.64 | +3.25% | 15.40M | NYSE | |||
| 19.95 | 20.10 | 19.81 | -0.05 | -0.25% | 36.84M | NYSE | |||
| 12.60 | 12.83 | 12.30 | +0.04 | +0.32% | 119.34K | NASDAQ | |||
| 24.90 | 25.12 | 24.90 | -0.16 | -0.64% | 44.43K | NYSE | |||
| 35.30 | 35.44 | 35.12 | -0.04 | -0.11% | 3.47M | NYSE | |||
| 23.38 | 23.58 | 23.13 | +0.10 | +0.43% | 563.43K | NASDAQ | |||
| 35.45 | 35.78 | 35.26 | +0.11 | +0.31% | 29.75M | NYSE | |||
| 1.90 | 1.92 | 1.90 | -0.010 | -0.52% | 315.88K | NYSE | |||
| 1.29 | 1.35 | 1.18 | +0.09 | +7.50% | 7.89M | NASDAQ | |||
| 8.88 | 8.98 | 8.82 | +0.03 | +0.34% | 80.14K | NYSE | |||
| 341.43 | 345.24 | 335.87 | -2.74 | -0.80% | 337.33K | NYSE | |||
| 1.90 | 2.27 | 1.75 | +0.32 | +20.25% | 2.12M | NASDAQ |